Los Angeles, CANCT06736574Now EnrollingIRB Ready

Heart Failure Clinical Trial in Los Angeles, CA

Access cutting-edge heart failure treatment through this phase 3 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Cytokinetics

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access heart failure specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this heart failure clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Heart Failure Study in Los Angeles

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Sponsor: Cytokinetics

Who Can Participate

Inclusion Criteria

Adult patients who meet all the following criteria at screening may be included in the study:
Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
Are receiving oral loop diuretics on a regular schedule
Patients without AFF on screening ECG:
LVEF \< 30% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 1000 pg/mL (BNP ≥ 300 pg/mL)
Patients with AFF on screening ECG:
LVEF \< 25% within 6 months of screening
Elevated N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) ≥ 3000 pg/mL (BNP ≥ 900 pg/mL)
Not currently taking digoxin
Meet one of the following criteria for a recent HF event:
Are currently hospitalized with the primary reason of HF
Had an HF event (as defined in the primary endpoint) within 12 months prior to screening. For the purposes of a qualifying HF event, subcutaneous furosemide will be treated as equivalent to intravenous furosemide Or
Had outpatient escalation of oral diuretics due to worsening signs and symptoms of heart failure plus one of two additional criteria sustained for at least 1 week: (1) at least 50% or 1.5-fold increase in daily loop-diuretic-equivalent dose; (2) the addition of a new diuretic class to a loop diuretic.
Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
Systolic blood pressure ≤ 140 mmHg

Exclusion Criteria

Any of the following criteria will exclude potential patients from the study:
Have AFF on the screening ECG and are currently taking digoxin
Have had any event or procedure that may have resulted in a change in ejection fraction, including, but not limited to, acute coronary syndrome and/or any coronary revascularization, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization, or cardiac contractility modulation therapy within 3 months of screening
Are admitted to a long-term care facility or hospice
Have a projected survival of \< 12 months due to non-cardiovascular causes based on clinical judgment
Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening (except for nocturnal supplemental oxygen for sleep apnea or heart failure)
Have an estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73m2 or receiving dialysis at screening
Have previously had a solid organ transplant
Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
Have received omecamtiv mecarbil in a previous clinical trial
Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP
Have primary infiltrative cardiomyopathy (e.g. cardiac amyloidosis) or severe stenotic valvular disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06736574) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in Los Angeles, CA

If you're searching for heart failure treatment options in Los Angeles, CA, this clinical trial (NCT06736574) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in Los Angeles, CA

See all heart failure clinical trials recruiting in Los Angeles — not just this study.

Browse Heart Failure Trials in Los Angeles →

Browse More Trials by Condition

Heart Failure TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA